Takeda opens development center in China

SHANGHAI and SINGAPORE -- Takeda Global Research and Development Asia, Pte Ltd and Takeda Shanghai Development Center (TSDC) announced the official opening of TSDC. The opening announcement was made in conjunction with a clinical development symposium organised by TSDC and China Center for Pharmaceutical International Exchange (CCPIE).

TSDC is based within the Shanghai-based Takeda (China) Holdings Co, Ltd, which is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (Osaka, Japan). This follows the announcement earlier this year by Takeda on the establishment of TSDC, which reinforces Takeda's strategic commitment to Asia and to China in particular.

Dr Benny Li, head of TSDC, said, "The establishment of TSDC provides a powerful addition to Takeda's global development infrastructure. The opening of TSDC will extend and enhance the company's clinical development activities within Asia with a focus on China for General Medicine and across Asia (outside Japan) for Oncology.”

China is the third largest pharmaceutical market in the world, and it is also said to be an especially strong oncology market.

“Through the addition of TSDC's capabilities, Takeda will continue to conduct high quality clinical trials which will lead to securing regulatory approvals in Asia,” Dr Li said.

With the addition of the TSDC, Takeda has enhanced its business in China through TCH's wholly owned subsidiaries, Takeda Pharmaceutical (China) Company Limited in Taizhou (Takeda China), which is responsible for marketing and sales, and Tianjin Takeda Pharmaceuticals Co, Ltd, in Tianjin (Tianjin Takeda), which is responsible for manufacturing. Together with Takeda China and Tianjin Takeda, TSDC will help to drive Takeda's ambitious growth agenda in China and in the broader Asian region.